文献速递肾小球疾病

肾小球疾病中糖皮质激素的减量策略

Glucocorticoid reduction in Glomerular Diseases.
PubMed 文献 · Kidney Int Rep · 2026-01-24

本综述综合随机对照及关键非对照研究,评估多种肾小球疾病中减少糖皮质激素暴露的策略。在ANCA相关血管炎中,减量方案维持疗效并降低感染风险;狼疮肾炎中低剂量及多靶点方案支持快速减量;微小病变肾病联合钙调磷酸酶抑制剂或霉酚酸酯可减少激素暴露;IgA肾病实践正转向避免激素。激素仍可能用于特定炎症性肾小球病的诱导,但角色可缩窄为早期限时使用。

要点

  • ANCA相关血管炎中减量糖皮质激素方案保持疗效并降低感染风险。
  • 狼疮肾炎低剂量策略及联合靶向药物支持更快减停激素。
  • IgA肾病实践正转向避免使用糖皮质激素。

核心结论

  • 糖皮质激素在肾小球疾病中仍具重要作用,但减量策略可在部分疾病中维持疗效并降低毒性。
  • 未来研究需明确静脉甲泼尼龙在快速进展表现中的最佳使用及更低剂量方案的安全性有效性。

研究设计与样本

  • 综述综合评估糖皮质激素减量策略的随机对照及关键非对照研究。

主要发现

  • 在ANCA相关血管炎中,PEXIVAS和LoVAS试验显示减量方案保持疗效并降低感染风险。
  • 在狼疮肾炎中,低剂量策略及早期联合贝利尤单抗、钙调磷酸酶抑制剂或奥妥珠单抗等多靶点方案支持更快减停。
  • 在微小病变肾病中,联合钙调磷酸酶抑制剂或霉酚酸酯可在较少激素暴露下达到缓解。
  • 在IgA肾病中,实践正转向避免糖皮质激素,整合靶向疾病特异性通路的新型免疫调节剂。

临床怎么用

  • 在ANCA相关血管炎中可考虑减量糖皮质激素方案以降低感染风险。
  • 在狼疮肾炎中可采用低剂量策略及联合靶向药物以加快激素减停。
  • 在微小病变肾病中可联合钙调磷酸酶抑制剂或霉酚酸酯以减少激素暴露。
  • 在IgA肾病中实践正转向避免使用糖皮质激素。
  • 糖皮质激素仍可用于特定炎症性肾小球病的诱导,但应限于早期限时使用。

局限性

  • 未来研究需解决静脉甲泼尼龙在快速进展表现中的最佳使用及更低剂量方案的安全性有效性等关键不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoids (GCs) remain central to the management of many glomerular diseases, providing rapid and potent antiinflammatory effects. However, their well-recognized toxicities have driven growing efforts to reduce cumulative exposure. This review synthesizes evidence from randomized and key noncontrolled studies evaluating GC-sparing strategies across diseases where these agents have historically played a central therapeutic role. In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), large trials such as the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) trial and the Effect of Reduced-Dose versus High-Dose Glucocorticoids Added to Rituximab (LoVAS) trial demonstrate that reduced-dose regimens preserve efficacy while lowering infection risk. In lupus nephritis (LN), lower-dose strategies and early use of multipronged regimens incorporating targeted agents such as belimumab, calcineurin inhibitors, or obinutuzumab support faster tapering. In minimal change disease (MCD), combination approaches with calcineurin inhibitors or mycophenolate achieve remission with less steroid exposure. In IgA nephropathy (IgAN), practice is increasingly shifting away from GC use altogether, as novel immunomodulatory agents targeting disease-specific pathways are integrated into care. Although GCs will likely remain essential for induction in select inflammatory glomerulopathies, their role can increasingly be narrowed to early, time-limited use. Future studies should address key uncertainties, particularly the optimal use of i.v. methylprednisolone in rapidly progressive presentations and evaluate the safety and efficacy of even lower-dose regimens.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Toal M, Canney M, Hesketh C, et al. Glucocorticoid reduction in Glomerular Diseases. Kidney Int Rep. 2026. PMID: 41732755. doi:10.1016/j.ekir.2026.103796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。